Bide Pharmatech Co. Ltd. A - Asset Resilience Ratio
Bide Pharmatech Co. Ltd. A (688073) has an Asset Resilience Ratio of 18.22% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Bide Pharmatech Co. Ltd. A for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Bide Pharmatech Co. Ltd. A's Asset Resilience Ratio has changed over time. See Bide Pharmatech Co. Ltd. A (688073) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Bide Pharmatech Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 688073 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥460.90 Million | 18.22% |
| Total Liquid Assets | CN¥460.90 Million | 18.22% |
Asset Resilience Insights
- Good Liquidity Position: Bide Pharmatech Co. Ltd. A maintains a healthy 18.22% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Bide Pharmatech Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Bide Pharmatech Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521 |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE |
Drug Manufacturers - Specialty & Generic | 1.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 20.24% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Bide Pharmatech Co. Ltd. A (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Bide Pharmatech Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.12% | CN¥75.52 Million ≈ $11.05 Million |
CN¥2.42 Billion ≈ $353.83 Million |
+3.12pp |
| 2023-12-31 | 0.01% | CN¥122.54K ≈ $17.93K |
CN¥2.42 Billion ≈ $353.39 Million |
-0.16pp |
| 2022-12-31 | 0.17% | CN¥3.97 Million ≈ $581.28K |
CN¥2.36 Billion ≈ $345.23 Million |
-7.92pp |
| 2020-12-31 | 8.08% | CN¥43.00 Million ≈ $6.29 Million |
CN¥531.90 Million ≈ $77.83 Million |
-- |
About Bide Pharmatech Co. Ltd. A
Bide Pharmatech Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. Its products are used in life sciences, organic chemistry, analytical chemistry, and other applications. The company was founded in 2007 and is based in Shanghai, China.